Table 5 Description of the trials assessing hypofractionation (HF)
Reference | Type | Cohort (HF) | HF | Mastectomy | Boost | Lymph node RT | 5-year LR |
|---|---|---|---|---|---|---|---|
Whelan [12] | P. | 622 | 42.5 Gy/16 fr | 0 % | 0 % | 0 % | PFS 97.2 % |
Owen [35] | P. | 940 | 42.9 Gy/13 fr | 0 % | 75 % | 21 % | 7 % |
39 Gy/13 fr | 9 % | ||||||
Start A [11] | P. | 1487 | 41.6 Gy/13 fr | 15 % | 61 % | 13.2 % | 3.2 % |
39 Gy/13 fr | 4.6 % | ||||||
Start B [10] | P. | 1110 | 40 Gy/15 fr | 8 % | 43.8 % | 7.4 % | 2 % |
Cutuli [2] | R. +CA | 133 | 32.5 Gy/5 fr | 0 % | 55 % | 48 % | 3.7 % |
Ortholan [14] | R. | 150 | 32.5 Gy/5 fr | 28.5 % | 33,00 % | 32 % | - |
Kirova [15] | R. +CA | 50 | 32.5 Gy/5 fr | 0 % | 0 % | - | - |